Retrospective study comparing six - and twelve-core prostate biopsy in detection of prostate cancer

Tobiume, Motoi; Yamada, Yoshiaki; Nakamura, Kogenta; Honda, Nobuaki

doi:10.1590/s1677-55382008000100003

Cited by 11 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of 36 patients who had the procedure under local anaesthetic none of the patients had post procedure complications like rectal bleeding, need for anaesthesia or prolongation of hospitalization. Similar studies by Tobiume et al 21 none of the patients showed rectal bleeding or need for anaesthesia, only few patients had minor complications.…”

Section: Correlation Of Complications Post Trus Biopsysupporting

confidence: 83%

Transrectal Ultrasonography Guided Prostate Biopsy in Evaluating Prostate Cancer with Histopathological Evaluation and Prostate Specific Antigen Correlation

Reddy¹,

Acharya²,

Khan³

et al. 2019

jemds

View full text Add to dashboard Cite

BACKGROUND Prostate cancer is the second most common cause of cancer related deaths among men in the United States. In India, prostate cancer affects 4-5 men per 100,000 population 1. Although it is a common disease, it is slow to manifest clinical signs. It is estimated that 30% of men over 45 yrs, harbor latent prostate cancer and will remain latent until death. The objective of the study was to evaluate the role of Transrectal Ultrasound (TRUS) guided biopsy with histopathological evaluation (HPE) in the detection of prostate cancer on the basis of elevated prostate-specific antigen levels (PSA). METHODS This prospective study was done on 36 patients who were referred to department of Radio-Diagnosis at Yenepoya Medical College Hospital, Mangalore for TRUS guided biopsy. TRUS guided biopsy was performed using the sextant core biopsy technique & samples were sent to the department of pathology for histopathological evaluation and results were documented. Results were analysed based on frequency and percentage. RESULTS Prostatic diseases were more common in the older age group and incidence increases with age. Most of the patients in our study had grade II prostatic enlargement. Our study showed diagnostic rate of 6 core biopsy with serum PSA levels 4-10 ng/ml was in 11.1% cases, while the diagnostic rate was 0% with serum PSA levels 11-20 ng/ml, 16.75% levels of 21-30 ng/ml, 25% with levels of 41-50 ng/ml and diagnostic rate was 100 % with serum PSA levels of >51 ng/ml, indicating strong correlation of PSA level with tumour diagnosis by TRUS guided biopsy. CONCLUSIONS TRUS guided sextant core biopsy is a safe and effective procedure in diagnosing prostate cancer and has high diagnostic rates for patients with PSA levels of >50 ng/ml and gland volume between 30-50 cc.

show abstract

Section: Correlation Of Complications Post Trus Biopsysupporting

confidence: 83%

Transrectal Ultrasonography Guided Prostate Biopsy in Evaluating Prostate Cancer with Histopathological Evaluation and Prostate Specific Antigen Correlation

Reddy¹,

Acharya²,

Khan³

et al. 2019

jemds

View full text Add to dashboard Cite

show abstract

“…Third, the bmiPCPTRC was built upon the original PCPTRC which relied on 6-core biopsies, and may lead to lower rates of PCa or HGPCa detection compared with the current standard of minimum 6-core biopsies. 29-30 Fourth, 614 men were excluded from the final analysis due to missing PSA, DRE, or BMI, and the PCa rate among these excluded men was significantly lower than those included in the analysis. This contributes to the higher PCa risk in the current cohort.…”

Section: Discussionmentioning

confidence: 99%

Is There a Role for Body Mass Index in the Assessment of Prostate Cancer Risk on Biopsy?

et al. 2014

View full text Add to dashboard Cite

Purpose To examine the role of body mass index (BMI) in assessment of prostate cancer (PCa) risk. Materials and Methods 3,258 participants who underwent biopsy (including 1,902 men with a diagnosis of PCa) were identified from the Selenium and Vitamin E Cancer Prevention Trial. The associations of BMI with PCa and high-grade PCa (HGPCa) were examined using logistic regression, adjusting for age, race, BMI-adjusted prostate-specific antigen, digital rectal exam, family history of PCa, previous biopsy history, PSA velocity and time between study entry and the last biopsy. The prediction models were compared with our previously-developed BMI-adjusted Prostate Cancer Prevention Trial prostate cancer Risk Calculator (bmiPCPTRC). Results Of the study subjects, 49.1% were overweight and 29.3% were obese. After adjustment, among men without a known family history of PCa, increased BMI was not associated with higher risk of PCa (per one-unit increase in logBMI: OR=0.83, p=0.54) but was significantly associated with higher risk of HGPCa (i.e., Gleason score≥7 prostate cancer) (OR=2.31, p=0.03). For men with a known family history of PCa, the risks of PCa and HGPCa increased rapidly as BMI increased (PCa: OR=3.73, p=0.02; HGPCa: OR=7.95, p=0.002). The bmiPCPTRC generally underestimated the risks of PCa and HGPCa. Conclusions BMI provided independently predictive information regarding risks of PCa and HGPCa, after adjusting for other risk factors. BMI, especially among men with a known family history of PCa, should be considered for inclusion in any clinical assessment of PCa risk and recommendations regarding prostate biopsy.

show abstract

“…Numerous studies have been conducted with different modifications in order to make it less invasive and to increase the sensitivity/specificity. 2,4,6 Recently, it has been asserted that the utilization of TRUS-pBx combined with targeted multiparametric magnetic resonance imaging (MRI) can improve prostate CDRs, especially the clinically significant ones, which is getting more and more popular. 8 It is believed that the zonal anatomy of the prostate and the number of biopsy cores are the key factors in the detection of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Comparison of prostate cancer detection rates between the Vienna nomogram and the 10-core biopsy protocol

et al. 2019

View full text Add to dashboard Cite

Objective: To compare the Vienna nomogram and the 10-core prostate biopsy protocol regarding whether there is superiority in prostate cancer detection. Methods: Between January and December 2012, a total of 215 patients applying to our outpatient clinic with lower urinary tract symptoms were evaluated, prospectively. Patients with a prostate-specific antigen level of 2.5–10 ng/mL and/or suspicious digital rectal examination were included in the study. Exclusion criteria were determined as recent pelvic radiotherapy, lower urinary tract surgery, history of acute urinary retention, or indwelling urinary catheter. Biopsies were taken systematically with at least 10 cores considering prostate volume and patient age. According to Vienna nomogram, in patients requiring 6- or 8-core biopsies, tissue sampling was completed to 10 cores (our standard protocol), whereas in patients requiring more than 10 cores additional tissue sampling was performed. Results: After the determination of inclusion/exclusion criteria, 170 patients were enrolled in our study. The median (min–max) age, prostate-specific antigen value, and prostate volume were 65 (48–86) years, 7.6 ng/dL (2.5–10), and 55 cc (17–150), respectively. Prostate cancer was detected in 49 (28.8%) patients with transrectal ultrasound–guided prostate biopsy according to the Vienna nomogram. We found that our standard 10-core biopsy protocol would have diagnosed prostate cancer in 46 (27.1%) patients in the same study group showing no statistically significant difference (p > 0.005). Conclusion: The findings of this study suggest that considering cancer detection rates no statistically significant differences were found between both methods. Further prospective research in this aspect is needed to define the ultimate prostate biopsy protocol.

show abstract

Retrospective study comparing six - and twelve-core prostate biopsy in detection of prostate cancer

Cited by 11 publications

References 21 publications

Transrectal Ultrasonography Guided Prostate Biopsy in Evaluating Prostate Cancer with Histopathological Evaluation and Prostate Specific Antigen Correlation

Transrectal Ultrasonography Guided Prostate Biopsy in Evaluating Prostate Cancer with Histopathological Evaluation and Prostate Specific Antigen Correlation

Is There a Role for Body Mass Index in the Assessment of Prostate Cancer Risk on Biopsy?

Comparison of prostate cancer detection rates between the Vienna nomogram and the 10-core biopsy protocol

Contact Info

Product

Resources

About